EUVIMEDEUVIMED entdecken
Crossref

4′-Ethynyl-2′-deoxy-2′-β-fluoro-2-fluoroadenosine: A Highly Potent and Orally Available Clinical Candidate for the Treatment of HIV-1 Infection

Jiao Hou, Youmei Peng, Bingjie Liu, Qianqian Zhang, Jian-Hua Wang, Wenquan Yu iD, Junbiao Chang iD

Journal of Medicinal Chemistry · 24.08.2023 · 66 (16) · 11282-11293

DOI: 10.1021/acs.jmedchem.3c00761 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 03.08.2023. Verfasst von Jiao Hou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Green Catalysis Center, and College of Chemistry, Zhengzhou University, Zhengzhou 450001, China. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections, HIV-1. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Central Plains Scholars and Scientists Studio Fund, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

2'-Deoxy-2'-β-fluoroadenosines bearing 4'-azido or 4'-ethynyl groups designed for the treatment of HIV-1 infection have been synthesized. All these compounds possess nanomolar anti-HIV-1 activity, with the 4'-ethynyl-2-fluoroadenosine analog 1c (CL-197) being the most potent compound with low cytotoxicity (EC50 = 0.9 nM, CC50 > 100 μM). It also shows potent inhibitory activities on drug resistant and clinical HIV-1 strains. Oral administration of 1c to Beagle dogs resulted in high levels of its bioactive form 1c-TP in peripheral blood mononuclear cells, the HIV-1 target cells, where the resulting triphosphate exhibited a long-term intracellular retention and could prevent HIV-1 infection for an extended time. 1c displayed low in vivo toxicity and favorable pharmacokinetics profiles in Sprague-Dawley rats. The preclinical data support further development of 1c as a highly potent and orally bioavailable clinical candidate to treat HIV-1 infection. Currently, CL-197 is in clinical trials in China (registration number: CXHL2200529).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV InfectionsHIV-1RatsAnimalsDogsLeukocytes, MononuclearRats, Sprague-DawleyAdenosine

Substanzen

Anti-HIV Agents2-fluoroadenosineAdenosine

Autor:innen und Institutionen

  • Green Catalysis Center, and College of Chemistry, Zhengzhou University, Zhengzhou 450001, China.
  • Henan Key Laboratory for Pharmacology of Liver Diseases, Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450052, China.
  • School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
  • Pingyuan Laboratory, State Key Laboratory of Antiviral Drugs, Henan Normal University, Xinxiang 453007, China.

ORCID-Profile: Wenquan Yu, Junbiao Chang

Förderung

  • National Key Research and Development Program of China
  • Central Plains Scholars and Scientists Studio Fund
  • National Natural Science Foundation of China
  • Young Backbone Teachers Fund of Henan Province
  • Henan Province Epidemic Prevention and Control Emergency Research Project

Zitieren

APA

Hou, J., Peng, Y., Liu, B., Zhang, Q., Wang, J. H., Yu, W., & Chang, J. (2023). 4′-Ethynyl-2′-deoxy-2′-β-fluoro-2-fluoroadenosine: A Highly Potent and Orally Available Clinical Candidate for the Treatment of HIV-1 Infection. Journal of Medicinal Chemistry, 66(16), 11282-11293. https://doi.org/10.1021/acs.jmedchem.3c00761

Vancouver

Hou J, Peng Y, Liu B, Zhang Q, Wang JH, Yu W, et al. 4′-Ethynyl-2′-deoxy-2′-β-fluoro-2-fluoroadenosine: A Highly Potent and Orally Available Clinical Candidate for the Treatment of HIV-1 Infection. Journal of Medicinal Chemistry. 2023;66(16):11282-11293. doi:10.1021/acs.jmedchem.3c00761

BibTeX
@article{Hou2023,
  author = {Hou, Jiao and Peng, Youmei and Liu, Bingjie and Zhang, Qianqian and Wang, Jian-Hua and Yu, Wenquan and Chang, Junbiao},
  title = {4′-Ethynyl-2′-deoxy-2′-β-fluoro-2-fluoroadenosine: A Highly Potent and Orally Available Clinical Candidate for the Treatment of HIV-1 Infection},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  volume = {66},
  number = {16},
  pages = {11282--11293},
  doi = {10.1021/acs.jmedchem.3c00761}
}
Kostenlos starten →